Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Howell

Showing results (241-250 of 260) with videos related to

Pageof 26
Sort By:
Acta Oncologica (Stockholm, Sweden)|January 1, 1989
Pharmacokinetics of intra-arterial mitomycin C with or without degradable starch microspheres (DSM) in the treatment of non-resectable liver cancerM Andersson, K F Aronsen, C Balch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990
A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancerS B Howell, S Kirmani, W E Lucas, et al.
International Journal of Cancer|August 4, 1998
Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatinD Fink, S Nebel, P S Norris, et al.
Cancer Research|November 1, 1991
Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatinS Isonishi, D K Hom, F B Thiebaut, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formationG Los, f A Blommaert, R Barton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2001
Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinomaA Bonetti, M Zaninelli, R Leone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancerG Los, K Benbatoul, D P Gately, et al.
Cancer Research|July 1, 1996
Loss of DNA mismatch repair in acquired resistance to cisplatinS Aebi, B Kurdi-Haidar, R Gordon, et al.
Cancer Research|March 15, 1987
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposideS Zimm, S M Cleary, W E Lucas, et al.
The Laryngoscope|June 17, 1998
Observations on control of N2 and N3 neck disease in squamous cell carcinoma of the head and neck by intra-arterial chemoradiationR A Weisman, R D Christen, V E Jones, et al.
Pageof 26

Showing results (241-250 of 260) with videos related to

Sort By:
Pageof 26
Acta Oncologica (Stockholm, Sweden)|January 1, 1989
Pharmacokinetics of intra-arterial mitomycin C with or without degradable starch microspheres (DSM) in the treatment of non-resectable liver cancerM Andersson, K F Aronsen, C Balch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990
A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancerS B Howell, S Kirmani, W E Lucas, et al.
International Journal of Cancer|August 4, 1998
Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatinD Fink, S Nebel, P S Norris, et al.
Cancer Research|November 1, 1991
Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatinS Isonishi, D K Hom, F B Thiebaut, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formationG Los, f A Blommaert, R Barton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2001
Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinomaA Bonetti, M Zaninelli, R Leone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancerG Los, K Benbatoul, D P Gately, et al.
Cancer Research|July 1, 1996
Loss of DNA mismatch repair in acquired resistance to cisplatinS Aebi, B Kurdi-Haidar, R Gordon, et al.
Cancer Research|March 15, 1987
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposideS Zimm, S M Cleary, W E Lucas, et al.
The Laryngoscope|June 17, 1998
Observations on control of N2 and N3 neck disease in squamous cell carcinoma of the head and neck by intra-arterial chemoradiationR A Weisman, R D Christen, V E Jones, et al.
Pageof 26